Logo Image
News|Articles|August 10, 2026

Health Plans, PBMs Wary of TrumpRx Impact on Patients

Key Takeaways

  • TrumpRx was launched as a White House most-favored-nation pricing vehicle, initially listing cash-pay discounts from five manufacturers and expanding participating products and companies over time.
  • AMCP respondents largely disagreed that TrumpRx delivers the lowest medication prices versus other channels, indicating weak perceived comparative value in real-world purchasing.
SHOW MORE

AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.

The Trump administration's direct-to-consumer drug price aggregation platform, TrumpRx, has been operating for more than six months, but a new survey of managed care professionals suggests widespread skepticism about whether it delivers real savings for patients.

In the first part of a video interview with Pharmaceutical Commerce, Adam Colborn, vice president of government affairs at the Academy of Managed Care Pharmacy (AMCP), breaks down the results of AMCP's member survey on TrumpRx and what they reveal about the platform's reception among managed care professionals.

TrumpRx launched in February as a White House initiative billed as a way to give patients access to discounted drugs priced in line with what other developed nations pay, a policy the administration calls most favored nation pricing. At launch, the site pointed to discounted, cash-pay products from five manufacturers that had struck pricing deals with the administration, with additional drugmakers and medications added in the months since.1

AMCP gathered 59 responses from members employed at health plans, pharmacy benefit managers, integrated delivery networks and consulting firms. Colborn notes that AMCP's respondents are not typically the type of healthcare professional who would refer a patient to TrumpRx. He says that's part of why AMCP was surprised that just over 15% of respondents had referred a friend or family member to the platform, since the survey also asked them in a personal capacity whether they or someone they know had used it.2

Among the findings Colborn highlights, a majority of respondents disagreed or strongly disagreed that TrumpRx offers patients the lowest available price for their medications, and more than half said they were concerned or extremely concerned about patients' ability to access medication through the program. He also notes the Federal Trade Commission's settlements with PBMs, including Express Scripts, which required standard plan offerings to eventually count TrumpRx purchases toward a patient's deductible once the regulatory groundwork is in place.3 Colborn says the results of the survey potentially indicate a disconnect between how TrumpRx is being marketed and how managed care professionals view its real-world value.

References
  1. The White House. "Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients." Feb. 5, 2026. https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/
  2. AMCP. "TrumpRx Member Survey." June 2026.
  3. Federal Trade Commission. "FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients." Feb. 4, 2026. https://www.ftc.gov/news-events/news/press-releases/2026/02/ftc-secures-landmark-settlement-express-scripts-lower-drug-costs-american-patients

Related Content